journal
MENU ▼
Read by QxMD icon Read
search

Urologic Oncology

journal
https://www.readbyqxmd.com/read/28641939/low-molecular-weight-protein-tyrosine-phosphatase-expression-as-a-prognostic-factor-for-men-with-metastatic-hormone-na%C3%A3-ve-prostate-cancer
#1
Mari Ohtaka, Yasuhide Miyoshi, Takashi Kawahara, Shinji Ohtake, Masato Yasui, Koichi Uemura, Shuko Yoneyama, Yusuke Hattori, Jun-Ichi Teranishi, Yumiko Yokomizo, Hiroji Uemura, Hiroshi Miyamoto, Masahiro Yao
OBJECTIVES: Recent studies have demonstrated that up-front docetaxel combined with androgen deprivation therapy (ADT) prolongs survival in some patients with metastatic hormone-naïve prostate cancer (mHNPC). However, new biomarkers for selecting personalized treatment strategies for mHNPC are warranted. We evaluated the value of low-molecular-weight protein tyrosine phosphatase (LMW-PTP) expression as a prognosticator in men with mHNPC. METHODS AND MATERIALS: A total of 48 men with mHNPC diagnosed from 2003 to 2009 were enrolled in this study...
June 19, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28624136/effect-of-abo-blood-type-on-the-outcomes-of-patients-with-metastatic-renal-cell-carcinoma-treated-with-first-line-tyrosine-kinase-inhibitors
#2
Kenji Omae, Shingo Fukuma, Tatsuyoshi Ikenoue, Tsunenori Kondo, Toshio Takagi, Hiroki Ishihara, Kazunari Tanabe, Shunichi Fukuhara
OBJECTIVES: To assess the effect of blood type on survival outcomes and adverse events (AEs) in patients treated with tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Patients who received TKIs as first-line therapy for mRCC between 2008 and 2015 at our hospital were included in the study (n = 136). Patients were divided into 2 groups based on their blood type as O and non-O. Survival outcomes and AEs were compared according to blood type...
June 14, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28623073/commentary-on-biallelic-inactivation-of-brca2-in-platinum-sensitive-metastatic-castration-resistant-prostate-cancer-cheng-hh-pritchard-cc-boyd-t-nelson-ps-montgomery-b-eur-urol-jun-2016-69-6-992-5
#3
Stephen Freedland, William Aronson
Understanding the molecular underpinnings of sensitivity to specific therapies will advance the goal of precision medicine in prostate cancer (PCa). We identified 3 patients with metastatic castration-resistant PCa (mCRPC) who achieved an exceptional response to platinum chemotherapy (not first-line treatment for PCa), despite disease progression on prior standard therapies. Using targeted next-generation sequencing on the primary and metastatic tumors, we found that all 3 patients had biallelic inactivation of BRCA2, a tumor suppressor gene critical for homologous DNA repair...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28623072/commentary-on-integrative-clinical-genomics-of-advanced-prostate-cancer-robinson-d-van-allen-em-wu-ym-schultz-n-lonigro-rj-mosquera-jm-montgomery-b-taplin-me-pritchard-cc-attard-g-beltran-h-abida-w-bradley-rk-vinson-j-cao-x-vats-p-kunju-lp-hussain-m-feng-fy
#4
Stephen J Freedland, William J Aronson
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28623071/overall-survival-in-swedish-patients-with-renal-cell-carcinoma-treated-in-the-period-2002-to-2012-update-of-the-rencomp-study-with-subgroup-analysis-of-the-synchronous-metastatic-and-elderly-populations
#5
Magnus Lindskog, Thomas Wahlgren, Rickard Sandin, Jan Kowalski, Maria Jakobsson, Sven Lundstam, Börje Ljungberg, Ulrika Harmenberg
BACKGROUND: This retrospective study investigated overall survival (OS) and factors influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the pre- (2002-2005), early (2006-2008), and late (2009-2012) targeted therapy (TT) era. METHODS: Three national Swedish registries identified patients with mRCC. Median OS was estimated using the Kaplan-Meier method. Multivariate analysis was performed using Cox proportional hazards regression...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28623070/commentary-on-inherited-dna-repair-gene-mutations-in-men-with-metastatic-prostate-cancer-pritchard-cc-mateo-j-walsh-mf-de-sarkar-n-abida-w-beltran-h-garofalo-a-gulati-r-carreira-s-eeles-r-elemento-o-rubin-ma-robinson-d-lonigro-r-hussain-m-chinnaiyan-a-vinson
#6
Stephen J Freedland, William J Aronson
BACKGROUND: Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established. METHODS: We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28619632/enhancing-prostate-cancer-survivorship-care-through-self-management
#7
REVIEW
Ted A Skolarus, Daniela Wittmann, Sarah T Hawley
The lack of clear roles for prostate cancer survivorship care providers places prostate cancer survivors at significant risk of inappropriate use of services delivered piecemeal by different providers, persistent bothersome symptoms, and silent suffering. Optimizing quality of care for prostate cancer survivors hinges on decreasing fragmentation of care, and providing quality symptom management. This is achieved through comprehensive, appropriate medical, surgical, pharmacological and psychosocial care, coupled with self-management, as highlighted in several recent resources addressing long-term and late effects of treatment...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28619634/enhancement-of-siglec-8-expression-predicts-adverse-prognosis-in-patients-with-clear-cell-renal-cell-carcinoma
#8
Chenzhang Ou, Li Liu, Jiajun Wang, Siyuan Dai, Yang Qu, Ying Xiong, Wei Xi, Jiejie Xu, Jianming Guo
PURPOSE: Sialic acid-binding immunoglobulin-like lectins (siglecs) family has important functions in tumor progression. The purpose of our study is to figure out the correlation between the expression level of Siglec-8 and prognosis of patients with clear cell renal cell carcinoma (ccRCC), and then to predict the overall survival (OS) via a novel nomogram. MATERIALS AND METHODS: A group of patients (n = 267) histologically diagnosed with ccRCC from Zhongshan Hospital were included into our study...
June 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28619633/time-to-progression-after-first-line-tyrosine-kinase-inhibitor-predicts-survival-in-patients-with-metastatic-renal-cell-carcinoma-receiving-second-line-molecular-targeted-therapy
#9
Hiroki Ishihara, Tsunenori Kondo, Kazuhiko Yoshida, Kenji Omae, Toshio Takagi, Junpei Iizuka, Kazunari Tanabe
OBJECTIVES: The effect of response to first-line tyrosine kinase inhibitor (TKI) therapy on second-line survival in patients with metastatic renal cell carcinoma who receive second-line molecular-targeted therapy (mTT) after first-line failure remains unclear. MATERIALS AND METHODS: Sixty patients who developed disease progression after first-line TKI, without prior cytokine therapy, were enrolled. According to the median first-line time to progression (1L-TTP), patients were divided into 2 groups (i...
June 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28619631/histopathologic-analysis-of-tumor-bed-and-peritumoral-pseudocapsule-after-in-vitro-tumor-enucleation-on-radical-nephrectomy-specimen-for-clinical-t1b-renal-cell-carcinoma
#10
Qun Lu, Changwei Ji, Xiaozhi Zhao, Yao Fu, Suhan Guo, Guangxiang Liu, Shiwei Zhang, Xiaogong Li, Weidong Gan, Hongqian Guo
PURPOSE: This study was designed to assess the feasibility and histopathologic safety of tumor enucleation for renal cell carcinoma, through histopathologic analysis of the tumor bed and peritumoral pseudocapsule (PC) after in vitro tumor enucleation. MATERIALS AND METHODS: We studied 176 radical nephrectomy specimens for clinical T1b renal cell carcinoma in our institution, from January 2013-February 2016. Immediately after the kidney was excised, the tumor of radical specimen was enucleated in vitro...
June 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28619630/hilar-fat-infiltration-a-new-prognostic-factor-in-metastatic-clear-cell-renal-cell-carcinoma-with-first-line-sunitinib-treatment
#11
Solène-Florence Kammerer-Jacquet, Angelique Brunot, Karim Bensalah, Boris Campillo-Gimenez, Mathilde Lefort, Sahar Bayat, Alain Ravaud, Frantz Dupuis, Mokrane Yacoub, Gregory Verhoest, Benoit Peyronnet, Romain Mathieu, Alexandra Lespagnol, Jean Mosser, Julien Edeline, Brigitte Laguerre, Jean-Christophe Bernhard, Nathalie Rioux-Leclercq
INTRODUCTION: The selection of patients with metastatic clear cell renal cell carcinoma (ccRCC) who may benefit from targeted tyrosine kinase inhibitors has been a challenge, even more so now with the advent of new therapies. Hilar fat infiltration (HFI) is a validated prognostic factor in nonmetastatic ccRCC (TNM 2009 staging system) but has never been studied in metastatic patients. We aimed to assess its phenotype and prognostic effect in patients with metastatic ccRCC treated with first-line sunitinib...
June 12, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28579283/optimizing-management-of-upper-tract-urothelial-carcinoma
#12
REVIEW
Matthew T Campbell, Amishi Y Shah, Surena F Matin, Arlene O Siefker-Radtke
Upper tract urothelial cancer (UTUC) is a rare cancer of the urothelium, comprising only a fraction of cases as compared to urothelial tumors of the bladder. As a result, systemic treatment approaches in bladder cancer are often applied to patients with UTUC. Given the anatomical location of these tumors, the age, the comorbid conditions of these patients with UTUC, and the need for radical nephroureterectomy for treatment, most patients have substantial impairment of renal reserve. There is growing evidence for the benefit of perioperative chemotherapy in this disease...
June 1, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28578871/subclassification-of-pn3-staging-systems-for-penile-cancer-proposal-for-modification-of-the-current-tnm-classification
#13
Zhiyong Li, Shengjie Guo, Zhiming Wu, Hui Han, Zaishang Li, Yanjun Wang, Dong Chen, Jieping Chen, Chuangzhong Deng, Zike Qin, Zhuowei Liu, Yonghong Li, Kai Yao, Fanjian Zhou
OBJECTIVE: To validate the clinical and prognostic significance of our proposed pN3 subclassification in penile cancer. MATERIALS AND METHODS: A retrospective analysis of 509 patients with penile cancer undergoing partial, total penectomy or inguinal lymphadenectomy or pelvic lymphadenectomy at Sun Yat-sen University Cancer Center was reevaluated by pathologists. pN3 stage was subclassified into pN3a (extranodal extension of any inguinal lymph node [LN] metastasis only) and pN3b (pelvic LN metastasis)...
May 31, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28572027/clinical-outcome-of-patients-who-reduced-sunitinib-or-pazopanib-during-first-line-treatment-for-advanced-kidney-cancer
#14
Roberto Iacovelli, Maria Cossu Rocca, Luca Galli, Ugo De Giorgi, Roberto Sabbatini, Matteo Santoni, Alessandra Mosca, Giuseppe Fornarini, Francesco Massari, Cristina Masini, Melissa Bersanelli, Elisa Biasco, Cristian Lolli, Annalisa Guida, Rossana Berardi, Carlo Terrone, Alessandro Pastorino, Andrea Ardizzoni, Carmine Pinto, Sebastiano Buti, Franco Nolè, Giampaolo Tortora
OBJECTIVES: To investigate the different outcomes in patients with metastatic renal cell carcinoma (mRCC) who receive a reduced first-line dose of sunitinib or pazopanib compared to those who continue at the standard dose. PATIENTS AND METHODS: All the patients treated in 11 oncological centers in Italy for mRCC who started first-line treatment with sunitinib or pazopanib at the standard dose. Descriptive statistical tests were used to highlight differences among groups...
May 29, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28572026/resistin-and-interleukin-6-as-predictive-factors-for-recurrence-and-long-term-prognosis-in-renal-cell-cancer
#15
Jukka Kallio, Mari Hämäläinen, Tiina Luukkaala, Eeva Moilanen, Teuvo L Tammela, Pirkko-Liisa Kellokumpu-Lehtinen
OBJECTIVES: The aim of the present study was to investigate prognostic factors for long-term outcome of renal cell cancer (RCC) in a cohort of patients treated before new antiangiogenic therapy modalities were introduced. Our specific aim was to explore resistin and interleukin 6 (IL-6) levels to find out cytokines potential to predict recurrence and survival in patients with RCC. MATERIALS AND METHODS: Our prospective study population consisted of 91 patients who underwent radical nephrectomy or partial resection for RCC at Tampere University Hospital between 1994 and 2001...
May 29, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28552465/experimental-validation-of-the-complement-protein-c3a-down-expression-in-the-plasma-of-patients-with-squamous-cell-carcinoma-of-the-penis
#16
Paulo Ornellas, Marilza de M Ribeiro-Carvalho, Antonio Augusto Ornellas, Luciano Scherrer, Leandro Koifman, Fulvio Magni, Maria Helena Ornellas, Gilda Alves
OBJECTIVES: We have previously shown the importance of the complement system in differentiating between patients with squamous cell carcinoma of the penis (SCCP) and controls. These patients had low expression of C3a and C4 fragments. Therefore, in this study, we investigated the complement protein C3a as a potential circulating biomarker in these patients by a commercially available enzyme-linked immunosorbent assay (ELISA) test. PATIENTS AND METHODS: Plasma samples from 39 patients with SCCP, 15 patients with prostate cancer, and 50 healthy male subjects were evaluated using the ELISA-Bioscience OptEIA Kit human anti-C3a (BD)...
May 25, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28551413/applying-the-chicken-embryo-chorioallantoic-membrane-assay-to-study-treatment-approaches-in-urothelial-carcinoma
#17
Margaretha A Skowron, Anuja Sathe, Andrea Romano, Michèle J Hoffmann, Wolfgang A Schulz, Gommert A van Koeveringe, Peter Albers, Roman Nawroth, Günter Niegisch
BACKGROUND: Rapid development of novel treatment options demands valid preclinical screening models for urothelial carcinoma (UC). The translational value of high-throughput drug testing using 2-dimensional (2D) cultures is limited while for xenograft models handling efforts and costs often become prohibitive for larger-scale drug testing. Therefore, we investigated to which extent the chicken chorioallantoic membrane (CAM) assay might provide an alternative model to study antineoplastic treatment approaches for UC...
May 25, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28551412/heterogeneity-in-renal-cell-carcinoma
#18
REVIEW
Alp Tuna Beksac, David J Paulucci, Kyle A Blum, Shalini Singh Yadav, John P Sfakianos, Ketan K Badani
INTRODUCTION: In recent years, molecular characterization of renal cell carcinoma has facilitated the identification of driver genes, specific molecular pathways, and characterization of the tumor microenvironment, which has led to a better understanding of the disease. This comprehension has revolutionized the treatment for patients with metastatic disease, but despite these advancements many patients will develop resistance leading to treatment failure. A primary cause of this resistance and subsequent treatment failure is tumor heterogeneity...
May 24, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28549821/effect-of-median-household-income-on-surgical-approach-and-survival-in-renal-cell-carcinoma
#19
Jacob Katsnelson, Rebecca J Barnes, Hunaiz A Patel, Daphne Monie, Theodor Kaufman, Nicholas J Hellenthal
PURPOSE: We sought to determine whether median household income (MHI) independently predicts surgical approach (partial vs. radical nephrectomy) and survival in patients with renal cell carcinoma. METHODS: The U.S. Surveillance Epidemiology and End Results Database (1988-2011) was queried to examine kidney cancer cases and linked to the Area Health Resources File. We correlated surgical approach and survival, both overall and cancer-specific, with tumor stage, age, race, sex, and income data...
May 23, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28533151/low-rates-of-androgen-deprivation-therapy-use-with-salvage-radiation-therapy-in-patients-with-prostate-cancer-after-radical-prostatectomy
#20
David D Yang, Vinayak Muralidhar, Brandon A Mahal, Michelle D Nezolosky, Shelby A Labe, Marie E Vastola, Ninjin Boldbaatar, Martin T King, Neil E Martin, Peter F Orio, Tni K Choueiri, Quoc-Dien Trinh, Robert B Den, Daniel E Spratt, Karen E Hoffman, Felix Y Feng, Paul L Nguyen
OBJECTIVE: The RTOG 9601 and GETUG-AFU 16 randomized controlled trials demonstrated that the addition of androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) improves progression-free and, for RTOG 9601, overall survival. We examined national trends in the use of ADT with SRT. MATERIALS AND METHODS: Of the 484,009 patients in the National Cancer Database from 2004 to 2012 with localized or locally advanced prostate cancer treated with radical prostatectomy (RP), 4,200 men received SRT (≥6mo after surgery)...
May 19, 2017: Urologic Oncology
journal
journal
32958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"